Intellia Therapeutics
NASDAQ: NTLACambridge, US · Founded 2014 · Delaware corporation · 505 employees on LinkedIn · 5 known investors
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Founders & leadership
Intellia Therapeutics was founded in 2014 by Nessan Bermingham and Jennifer Doudna.
NB
Nessan BerminghamCo-founder
JD
Jennifer DoudnaCo-founder
JR
Jose RiveraExecutive
JL
John LeonardPresident and Chief Executive Officer
JB
James BastaExecutive Vice President, General Counsel and Corporate Secretary
ED
Edward DulacExecutive Vice President, Chief Financial Officer
BS
Birgit SchultesExecutive Vice President, Chief Scientific Officer
MS
Marika St. AmandSenior Vice President, Chief Human Resources Officer
Board
CG
Carl GordonBoard director
JF
RH
Rachel HaurwitzBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$70M disclosed across 1 of 2 rounds · 2015–2026
▶$70MraisedSep 2015 · 28 investors · BiotechnologyRule 506(b)
▶$70MraisedSep 2015 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nessan BerminghamExecutive Officer, Director
- Jose RiveraExecutive Officer
- Carl GordonDirector
- Jean-Francois FormelaDirector
- John LeonardExecutive Officer, Director
- Rachel HaurwitzDirector
- Offering amount
- $70M
- Amount sold
- $70M
- Sales commissions
- $2.3M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBYJU'S165 shared keywordsBYJU'S offers online learning programs, video lessons, and a personalized learning app for students in India, including tutoring and exam-preparation programs for competitive tests such as JEE and NEET.
Massive Bio139 shared keywordsMassive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Companies competing with Intellia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Simply Wall St Newssimplywall.st · Aug 2026Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Intellia Therapeutics do?
- Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
- Who founded Intellia Therapeutics?
- Intellia Therapeutics was founded by Nessan Bermingham, Jennifer Doudna in 2014.
- Who are Intellia Therapeutics's investors?
- Intellia Therapeutics's investors include age1, Atlas Venture, Avoro Capital Advisors, EcoR1 Capital, Foresite Capital.
- How much funding has Intellia Therapeutics raised?
- Intellia Therapeutics has disclosed $70M raised across 1 of its 2 known rounds.
- Where is Intellia Therapeutics headquartered?
- Intellia Therapeutics is headquartered in Cambridge, US.